Citigroup
APLS

Citigroup’s Apellis Pharmaceuticals APLS Stock Holding History

Citigroup’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.41M Buy
+60,000
New +$1.29M ﹤0.01% 2550
2025
Q1 		– Sell
-29,000
Closed -$925K – 5555
2024
Q4 		$925K Buy
+29,000
New +$872K ﹤0.01% 3420
2024
Q2 		– Sell
-89,700
Closed -$5.27M – 5570
2024
Q1 		$5.27M Buy
+89,700
New +$5.72M ﹤0.01% 1675
2023
Q4 		– Sell
-30,000
Closed -$1.14M – 5683
2023
Q3 		$1.14M Buy
30,000
+28,400
+1,775% +$1.25M ﹤0.01% 2398
2023
Q2 		$146K Sell
1,600
-23,300
-94% -$2.01M ﹤0.01% 4052
2023
Q1 		$1.64M Buy
24,900
+200
+0.8% +$11.5K ﹤0.01% 2158
2022
Q4 		$1.28M Sell
24,700
-10,300
-29% -$546K ﹤0.01% 2399
2022
Q3 		$2.39M Buy
+35,000
New +$2.07M ﹤0.01% 2023

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citigroup's APLS Position: Q1 2026 in Review

Citigroup increased its Apellis Pharmaceuticals (APLS) stake by 5.6% in Q1 2026, buying an estimated $756K and bringing the position to 657,223 shares worth $26.4M. The position accounts for 0.01% of the portfolio, ranked #929.

Citigroup first reported a position in APLS in Q4 2017 and has held it in 34 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Citigroup held 657,223 shares of Apellis Pharmaceuticals worth $26.4M as of Q1 2026.
  • Citigroup bought 35,065 Apellis Pharmaceuticals shares in Q1 2026, an estimated $756K.
  • Apellis Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #929 holding.
  • Citigroup first reported a position in Apellis Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.